secwatch.observer — SEC 8-K summary
======================================

Issuer:     AVITA Medical, Inc. (RCEL)
CIK:        0001762303
Form:       8-K
Filed at:   2026-01-13T23:59:59+00:00
Accession:  0001193125-26-011167
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 1.02, 2.02, 2.03, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AVITA Medical: Q4 rev ~$17.6M, FY2025 $71.6M; new $60M credit facility; FY2026 guidance $80-85M
--------------------------------------------------------------------------------

- Q4 2025 revenue ~$17.6M (vs $18.4M Q4 2024); Cohealyx-I fully enrolled, PermeaDerm-I >75% enrolled in Dec 2025.
- FY2025 revenue $71.6M, up 11% YoY from $64.3M in 2024, within revised guidance.
- FY2026 revenue guidance $80-85M (12-19% growth); TTM revenue covenant $68.5M for Q1 2026, $73M for FY2026.
- New $60M credit facility with Perceptive Advisors ($50M funded, $10M option until Q1 2027); SOFR+7.5% (4% floor).
- Warrant to purchase 500k shares (additional 150k if $10M drawn) at VWAP-based price; 10-year term; registration rights.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1762303/000119312526011167/0001193125-26-011167-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1762303/000119312526011167/rcel-20260113.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-011167

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer